ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients

Niclas Björn,Ingrid Jakobsen-Falk,Ignace Vergote,Henrik Gréen

ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients

2018

Niclas Björn
Ingrid Jakobsen-Falk
Ignace Vergote
Henrik Gréen

The standard chemotherapy for ovarian cancer is paclitaxel/carboplatin. Patients often exhibit myelosuppressive toxicity, and the treatment response varies considerably. In this study, we investiga ...

Keywords:

Ovarian cancer
Biochemistry
Progression-free survival
Oncology
Diabetes mellitus
Paclitaxel carboplatin
Medicine
Internal medicine
Toxicity
overall survival
Paclitaxel
Carboplatin
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations